Ascentage Pharma Group International (NASDAQ:AAPG) Shares Climb 4% – Time to Buy?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) traded up 4% during trading on Monday. The company traded as high as $15.19 and last traded at $15.3390. Approximately 2,606 shares changed hands during trading, a decline of 62% from the average daily volume of 6,799 shares. The stock had previously closed at $14.75.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Citizens Jmp began coverage on shares of Ascentage Pharma Group International in a research report on Tuesday. They set a “market outperform” rating and a $35.00 price target for the company. Citigroup began coverage on Ascentage Pharma Group International in a research note on Tuesday. They set an “outperform” rating on the stock. JPMorgan Chase & Co. lowered their target price on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a report on Thursday, October 8th. Finally, BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $43.67.

Ascentage Pharma Group International Trading Down 1.6%

The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09. The firm has a fifty day simple moving average of $16.65 and a 200 day simple moving average of $19.22.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million for the quarter. On average, equities research analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.